Strategic Partnerships Helio Genomics has established commercial partnerships with Quest Diagnostics and Syneos Health, creating ready-made distribution channels and lab workflows to reach physicians and patients. This network presents a rapid path to scale HelioLiver and other early-detection tests, with opportunities for co-marketing, integrated testing programs, and joint pilots in oncology and hepatology.

Portfolio Expansion With a multi-modal x multi-omics biomarker discovery approach and an expanding test portfolio centered on early cancer detection, notably HelioLiver for HCC, there are clear upsell opportunities to convert current lab customers into a broader diagnostic suite. Cross-sell to GI, hepatology, and oncology services within existing partner networks and hospital systems.

Regulatory Edge The presence of CLIA and CAP certified labs, ISO 13485 compliance, and cGMP facilities provides a strong regulatory and quality narrative. This de-risks customer procurement, speeds test approval in new regions, and supports enterprise-level deals with large health systems that require rigorous quality controls.

Global Access With US and China collaborations and offices in California and Indiana, Helio Genomics can leverage international partnerships to accelerate deployment in diverse healthcare markets, align with global health initiatives, and tailor value propositions for labs and systems that operate across borders.

Clinical Validation Strong clinical validation and recognition through top abstracts and awards at liver cancer symposia, along with press coverage, position Helio Genomics as a credible partner for early cancer detection trials. These data points can underpin payer discussions, clinician adoption, and pilot programs with health systems and labs.